APA Zitierstil

Ardini, E., & Siena, S. (2020). Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic NTRK targeted cancer therapies. ESMO Open.

Chicago Zitierstil

Ardini, Elena, und Salvatore Siena. "Entrectinib Approval By EMA Reinforces Options for ROS1 and Tumour Agnostic NTRK Targeted Cancer Therapies." ESMO Open 2020.

MLA Zitierstil

Ardini, Elena, und Salvatore Siena. "Entrectinib Approval By EMA Reinforces Options for ROS1 and Tumour Agnostic NTRK Targeted Cancer Therapies." ESMO Open 2020.

Achtung: Diese Zitate sind unter Umständen nicht zu 100% korrekt.